Parameter
| Biomarker | Sclerostin | Full name | seric scleroprotein | Molecular Type | protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | inhibition of bone formation | ||
| Disease | Osteoporosis (OP) | Disease Subtypes | / | ||
| Organ | Bone | Test Sample / Technology Platform | Serum (ELISA, electrochemiluminescence assay) | ||
| Pathobiological Mechanisms | Secreted by osteocytes, it inhibits osteoblast differentiation by blocking the Wnt/β-catenin pathway, and elevated levels after menopause exacerbate bone formation inhibition. | ||||
| Clinical Availability Status | Clinical trials in progress | ||||
| Notes and Dynamics | negatively correlated with lumbar BMD (r=-0.38); the degree of reduction in levels after treatment with sclerosing protein antibody (Romosozumab) was positively correlated with BMD increase | ||||